What is the recommended management and treatment protocol for a child with nephrotic syndrome, including initial steroid therapy, use of diuretics and ACE inhibitors, and options for steroid‑resistant cases?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Paediatric Nephrotic Syndrome

For initial presentation of idiopathic nephrotic syndrome in children over 1 year, start oral prednisone at 60 mg/m²/day (maximum 60 mg) as a single daily dose for 6 weeks, followed by 40 mg/m² on alternate days for another 6 weeks, then taper by 10 mg/m²/week to 5 mg on alternate days—total duration 16 weeks. 1

Initial Steroid Therapy Protocol

First Episode Treatment

The cornerstone of management is corticosteroid therapy for at least 12 weeks 2. The specific regimen:

  • Daily phase: Prednisone 60 mg/m²/day (or 2 mg/kg/day, maximum 60 mg) as single morning dose for 6 weeks 1
  • Alternate-day phase: 40 mg/m² on alternate days for 6 weeks 1
  • Tapering phase: Reduce by 10 mg/m²/week until reaching 5 mg on alternate days (additional 4 weeks) 1
  • Total duration: 16 weeks 1

Critical caveat: Children under 1 year likely have genetic/congenital causes and should be managed differently—do not empirically treat with steroids 2.

Defining Remission and Relapse

  • Remission: Urine dipstick trace/negative for proteinuria for at least 3 consecutive days 1
  • Relapse: ≥2+ proteinuria on early morning urine for 3 consecutive days, or ≥2+ proteinuria with edema 1

Steroid Resistance Definition

Steroid resistance is defined after a minimum of 8 weeks of corticosteroid therapy; if no remission by 6 weeks, SRNS diagnosis is confirmed 1. This is crucial—do not prematurely label children as steroid-resistant.

Management of Relapses

Infrequent Relapses

For children with infrequent relapses (fewer than 2 relapses in 6 months or 4 in 12 months):

  • Prednisone 60 mg/m²/day (maximum 60 mg) until remission for at least 3 consecutive days 1
  • Then switch to 40 mg/m² on alternate days for at least 4 weeks 2

Frequently Relapsing (FR) or Steroid-Dependent (SD) Nephrotic Syndrome

For relapses in FR/SD cases:

  • Prednisone 60 mg/m²/day until remission (3 consecutive days) 1
  • Then 40 mg/m² on alternate days for 1 week
  • Taper by 10 mg/m²/week to complete 4 weeks total 1

Important update from 2025 KDIGO: Daily glucocorticoids should NOT be routinely given during upper respiratory tract infections to prevent relapses in FR/SD patients, as the PREDNOS2 study showed no benefit 3. This reverses previous practice.

Steroid-Sparing Agents for FR/SD Disease

When to use: For children with FR nephrotic syndrome who develop serious glucocorticoid-related adverse effects, and for ALL children with SD nephrotic syndrome 3.

Choice of Agent

The 2025 KDIGO guideline no longer distinguishes "first-line" versus "alternative" agents 3. Instead:

For Frequently Relapsing NS:

  • Oral cyclophosphamide or levamisole are preferable 3
  • Levamisole is first-line if available, then cyclophosphamide 1

For Steroid-Dependent NS:

  • Mycophenolate mofetil, rituximab, calcineurin inhibitors (CNI), or oral cyclophosphamide may be preferable 3

Specific Dosing

  • Levamisole: First-line steroid-sparing agent when available 1
  • Cyclophosphamide IV: 500 mg/m² per dose, given monthly for 4 months 1
  • Calcineurin inhibitors: Should be continued for minimum 6 months, then stopped if partial remission not achieved 1; if partial/complete remission achieved by 6 months, continue for minimum 12 months 1

Key principle: Patients should ideally be in remission with glucocorticoids before starting steroid-sparing agents, and continue glucocorticoids for 2 weeks after initiating these agents 3.

Steroid-Resistant Nephrotic Syndrome (SRNS)

Evaluation Requirements

Before or immediately after confirming SRNS 1:

  • Renal biopsy (Grade A, strong recommendation)—except in known infection/malignancy-associated disease or confirmed genetic/familial cases
  • Genetic testing (Grade B, moderate recommendation)—ideally within 2 weeks
  • Baseline kidney function (GFR or eGFR)
  • Quantify proteinuria (urine protein/creatinine ratio)

Treatment of SRNS

First-line therapy: Calcineurin inhibitors (cyclosporine or tacrolimus) 3, 4, 5, 6.

  • CNIs versus IV cyclophosphamide: CNIs increase complete/partial remission at 3-6 months (RR 1.98) and reduce treatment failure (RR 0.32) compared to IV cyclophosphamide 6
  • Continue CNI for minimum 6 months; stop if no partial remission achieved 1
  • If partial/complete remission by 6 months, continue for minimum 12 months 1
  • Consider discontinuation after 12-24 months to reduce nephrotoxicity risk 1

In resource-limited settings: If biopsy/genetic testing unavailable, start CNI immediately. If CNI unavailable, use IV or oral cyclophosphamide 1.

Emerging option: Rituximab may achieve remission in approximately 30% of children with CNI-resistant SRNS 3.

Supportive Management

Diuretics and Volume Assessment

Critical distinction: Assess for hypovolemia before administering diuretics, as one-third of edematous children with nephrotic syndrome have hypovolemia, and 50% of these are asymptomatic 7.

Surrogate markers for hypovolemia (in descending order of sensitivity) 7:

  • High hematocrit (80% sensitive)
  • Serum albumin <1.5 g/dL (56.6% sensitive)
  • IVC collapsibility index ≥50% (43% sensitive, 91.6% specific)
  • Severe edema (36.7% sensitive)
  • Blood urea/creatinine ≥100:1 (33.3% sensitive)

Diagnostic test for hypovolemia: FeNa <0.5 AND urinary potassium index ≥0.6 7.

Diuretic choice: Torsemide is NOT superior to furosemide in children with nephrotic syndrome 8. Use furosemide 1-1.5 mg/kg twice daily for moderate to severe edema without hypovolemia 8. For progressive edema despite oral diuretics, escalate to IV furosemide with 20% human albumin 9.

ACE Inhibitors/ARBs

ACE inhibitors or ARBs reduce proteinuria in SRNS and are recommended as adjuvant agents 5. The dual angiotensin II and endothelin Type A receptor antagonist sparsentan may reduce proteinuria more effectively than ARBs alone 6.

Infection Prophylaxis

Penicillin V prophylaxis should be initiated for spontaneous bacterial peritonitis prevention in children with significant hypoalbuminemia and ascites 9.

Indications for Kidney Biopsy

Perform kidney biopsy in children with steroid-sensitive nephrotic syndrome if 1:

  • Late-onset steroid resistance
  • Age <1 year or >12 years at diagnosis
  • Suspicion of secondary cause
  • Assessment of CNI nephrotoxicity

Common Pitfalls to Avoid

  1. Do not label as steroid-resistant before 6-8 weeks of adequate corticosteroid therapy 1
  2. Do not give prophylactic steroids during infections in FR/SD patients—this practice is no longer recommended 3
  3. Do not administer diuretics without assessing volume status—hypovolemia is present in one-third of edematous children 7
  4. Do not delay genetic testing in SRNS—results should ideally be available within 2 weeks 1
  5. Do not continue CNI beyond 6 months without achieving at least partial remission 1
  6. Monitor CNI trough levels, blood pressure, and renal function regularly to detect calcineurin inhibitor toxicity 9

References

6
Research

Interventions for idiopathic steroid-resistant nephrotic syndrome in children.

The Cochrane database of systematic reviews, 2019

Related Questions

What is the recommended evaluation and management for a child presenting with nephrotic syndrome?
In a patient on the fifth month of methylprednisolone (Medrol) who still has proteinuria greater than 1 g/24 h with hypertension and edema, what is the next step in management?
What are the classifications of nephrotic syndrome based on steroid response and the recommended management for each category?
What is the recommended management, including steroid therapy and monitoring, for an adult patient with a childhood history of hospitalization for kidney disease in the 1940s who received three months of steroid injections?
What is the management plan for a 12-year-old boy presenting with two days of periorbital edema, proteinuria, serum albumin of 2.5 g/dL, and a 1 kg weight gain?
In a patient with stable Crohn’s disease on mesalazine who has partially controlled facial swelling, what is the appropriate treatment plan?
Is it safe for an infant with oral injuries (tooth, gum, or palate trauma) to continue breastfeeding, and when should we switch to expressed milk?
In a Crohn’s disease patient on mesalazine who developed facial swelling that was initially attributed to rosacea, how should the swelling be evaluated and managed?
What is the appropriate management of hyperkalemia?
How should mild hypermagnesemia (serum magnesium 2.8 mg/dL) be managed?
Can you interpret the MRI findings for a 68-year-old patient with acute left hip pain that began after bending, now medial, limiting hip flexion and leg elevation, occasionally radiating to the knee, with no back pain, currently taking acetaminophen (Tylenol)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.